

To: Keystone First/Keystone First Community HealthChoices (CHC) Providers

Date: February 10, 2021

**UPDATE: The Pennsylvania Department of Human Services (DHS) released a new Medical Assistance Bulletin (MAB) addressing additional CPT codes for the administration of SARS-CoV-2 Vaccines and reimbursement changes.**

Keystone First/Keystone First CHC (the “Plan”) will follow the updated guidelines issued on January 26, 2021 by the Department of Human Service (DHS) Medical Assistance Bulletin (MAB) (01-20-62, 08-20-65, 09-20-60, 24-20-54, 31-20-62, 33-20-57) outlining and updating the addition of newly created Current Procedural Terminology (CPT) codes for the administration of the novel coronavirus (SARS-CoV-2) vaccines and reimbursement changes.

**What is new?**

1. DHS made the decision to increase the MA Program fee schedule rate to that of Medicare for the administration of the SARS-CoV-2 vaccines. The Plan will follow that guidance and update our systems.
2. This rate increase is effective December 1, 2020. Providers do not need to resubmit claims; the Plan will reprocess and adjust payment.
3. The complete MAB, outlining the procedure code, national code description, provider type, provider specialty, place of service, pricing and/or informational modifiers if applicable, etc. can be found on the Coronavirus Vaccine section of the website at [www.keystonefirstpa.com](http://www.keystonefirstpa.com) or [www.keystonefirstchc.com](http://www.keystonefirstchc.com)
4. CPT codes have been added to the list below for vaccines manufactured and administered by AstraZenca.

Effective December 1, 2020 the following CPT codes have been added to the Keystone First/Keystone First CHC fee schedule.

Vaccine Manufacturer	Code	Code Description
Pfizer, Inc.	0001A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (Coronavirus diseases [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; first dose
	0002A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (Coronavirus diseases [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; second dose
Moderna, Inc.	0011A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (Coronavirus diseases [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage; first dose

Vaccine Manufacturer	Code	Code Description
	0012A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (Coronavirus diseases [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5 mL dosage; second dose
AstraZeneca	0021A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector, preservative free, 5x10 <sup>10</sup> viral particles/0.5mL dosage; first dose
	0022A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector, preservative free, 5x10 <sup>10</sup> viral particles/0.5mL dosage; second dose

Please continue to visit the dedicated coronavirus page on the provider websites for the most up-to-date information and links to updates from DHS and the Pennsylvania Department of Health (DOH).